ArticlePediatric research2026
Combination of CHK1 and CHK2 inhibitors exerts synergistic antitumor effects against neuroblastoma cells.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroblastoma, the most common extracranial solid tumor in children, is often associated with high-risk features and poor outcomes. Despite intensive multimodal therapies, survival remains unsatisfactory, underscoring the need for new treatments. Checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2) are key regulators of the DNA damage response (DDR) and cell cycle checkpoints. We investigated the antitumor effect of their combined inhibition in neuroblastoma.
methodsNeuroblastoma cell lines were treated with the CHK1 inhibitor LY2606368 and CHK2 inhibitor PV1019, either individually or in combination. Cell viability was measured using the WST-8 assay. Cell cycle distribution was analyzed by flow cytometry following propidium iodide staining. DNA damage and replication stress were assessed by immunofluorescence and western blotting for γH2AX and phospho-RPA2 (S8), respectively. Apoptosis was evaluated using sub-G1 population analysis, detection of cleaved-PARP and cleaved-caspase-3, and TUNEL staining.
resultsCo-treatment showed synergistic activity against both MYCN-amplified and non-amplified cell lines. Combination treatment reduced cell numbers more effectively than either agent alone, increased S-phase entry, and enhanced DNA damage, replication stress, and apoptosis marker expression.
conclusionDual CHK1/CHK2 inhibition disrupts the DDR and checkpoints, leading to replication stress, DNA damage, and apoptosis, representing a promising therapeutic strategy for neuroblastoma. IMPACT: Combined CHK1/CHK2 inhibitor therapy shows a synergistic anti-tumor effect against neuroblastoma cells. Combination therapy impairs DNA damage response pathways and drives accelerated cell cycle progression in neuroblastoma cells. Combination therapy increases DNA damage, replication stress, and apoptosis marker expression. Combined CHK1/CHK2 inhibition holds therapeutic potential for the treatment of neuroblastoma.
Identifiers
42230907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.